Yang J, Shen N, Shen J, Yang Y, Li HL. Complicated role of post-translational modification and protease-cleaved fragments of tau in Alzheimer’s Disease and other tauopathies. Mol Neurobiol. 2024;61(7):4712–31.

Article  CAS  PubMed  Google Scholar 

Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-Beta might explain Efficacy and Side effects in clinical trials for Alzheimer’s Disease. Neurotherapeutics: J Am Soc Experimental Neurother. 2023;20(1):195–206.

Article  Google Scholar 

Bespalov A, Courade JP, Khiroug L, Terstappen GC, Wang Y. A call for better understanding of target engagement in Tau antibody development. Drug Discov Today. 2022;27(11):103338.

Article  CAS  PubMed  Google Scholar 

Imbimbo BP, Balducci C, Ippati S, Watling M. Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story. Neural Regeneration Res. 2023;18(1):117–8.

Article  Google Scholar 

Courade JP, Angers R, Mairet-Coello G, Pacico N, Tyson K, Lightwood D, et al. Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer tau. Acta Neuropathol. 2018;136(5):729–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barini E, Plotzky G, Mordashova Y, Hoppe J, Rodriguez-Correa E, Julier S, et al. Tau in the brain interstitial fluid is fragmented and seeding-competent. Neurobiol Aging. 2022;109:64–77.

Article  CAS  PubMed  Google Scholar 

Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.

Article  PubMed  Google Scholar 

Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547(7662):185–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horie K, Barthélemy NR, Spina S, VandeVrede L, He Y, Paterson RW, et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. Nat Med. 2022;28(12):2547–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Nguyen BA, Mullapudi V, Li Y, Saelices L, Joachimiak LA. Disease-associated patterns of acetylation stabilize tau fibril formation. Structure (London, England: 1993). 2023.

Trzeciakiewicz H, Tseng JH, Wander CM, Madden V, Tripathy A, Yuan CX, et al. A dual pathogenic mechanism links tau acetylation to sporadic Tauopathy. Sci Rep. 2017;7:44102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song HL, Kim NY, Park J, Kim MI, Jeon YN, Lee SJ et al. Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280-acetylated tau in cell and mouse models. J Clin Investig. 2023;133(8).

Xia Y, Prokop S, Giasson BI. Don’t Phos over tau: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies. Mol Neurodegener. 2021;16(1):37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parra Bravo C, Krukowski K, Barker S, Wang C, Li Y, Fan L, et al. Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury. Mol Neurodegeneration. 2024;19(1):1–19.

Article  Google Scholar